Business Context and Reporting Period
This Form 8-K is filed by Heatwurx, Inc. (not Processa Pharmaceuticals, Inc.) for the reporting period ending February 28, 2014. The company is incorporated in Delaware and is based in Greenwood Village, Colorado. The filing primarily addresses unregistered sales of equity securities and the commencement of a new debt offering.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, or cash flow data. Specific capitalization metrics disclosed include:
- Debt Financing Completed: $500,000 in additional notes sold on February 28, 2014.
- Total Debt Raised: $850,000 aggregate principal under the current financing program.
- Warrants Issued: 166,664 warrants issued in the February transaction; 283,329 total warrants issued to date under this program.
- Interest Rate: 12% per annum on promissory notes.
- Liquidity: Proceeds are designated for satisfying outstanding debt and providing working capital.
Material Changes
The primary material change is the completion of a $500,000 tranche of debt financing, bringing the total raised under the existing Loan Agreement to $850,000. Additionally, the company announced the commencement of a new non-public offering on March 1, 2014, with a target of up to $3,000,000.
Guidance, Outlook, and Risks
Outlook and Use of Proceeds: The new offering is intended to remain open until December 31, 2014. Proceeds will be used to pay down existing debt and fund working capital operations.
Terms of New Offering: Notes bear 12% interest with principal due January 6, 2016. Investors receive one warrant for every $3.00 loaned, exercisable immediately at $3.00 per share.
Risks and Contingencies: The securities are sold unregistered under Section 4(a)(5), 4(a)(2), and Rule 506(b) exemptions. They are restricted to accredited investors and cannot be resold in the U.S. without registration or an applicable exemption. The company reserves the right to terminate the new offering early.
Investor Verification Checklist
- Verify the discrepancy between the requested company name (Processa Pharmaceuticals) and the filing registrant (Heatwurx, Inc.).
- Confirm the total outstanding debt load, as the filing only details the $850,000 raised under the specific Loan Agreement.
- Assess the company's ability to service the 12% interest payments and repay the $850,000 principal by January 2016.
- Review the dilution impact of the 283,329 warrants already issued and the potential issuance of up to 1,000,000 additional warrants under the new $3M offering.
- Confirm the status of the "outstanding debt" mentioned as a use of proceeds for the new offering.